Tiotropium increases cytosolic muscarinic M3 receptors and acetylated H3 histone proteins in induced sputum cells of COPD patients

European Journal of Medical Research

Volumn 15, Issue 2, 2010, Pages 64-67

  Holownia, Adam ^a   Mroz, R M ^a   Skopinski, T ^a   Kielek, A ^a   Kolodziejczyk, A ^a   Chyczewska, E ^a   Braszko, J J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

chromatin; COPD; histone acetylation; M3 receptors; tiotropium

Indexed keywords

HISTONE DEACETYLASE 2; MUSCARINIC M3 RECEPTOR; TIOTROPIUM BROMIDE; HISTONE; SCOPOLAMINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG PROTEIN BINDING; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; ACETYLATION; CHEMISTRY; CYTOLOGY; CYTOSOL; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; SPUTUM; VITAL CAPACITY;

ACETYLATION; CYTOSOL; FORCED EXPIRATORY VOLUME; HISTONES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, MUSCARINIC M3; SCOPOLAMINE DERIVATIVES; SPUTUM; VITAL CAPACITY;

EID: 79952277838     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-15-S2-64     Document Type: Article

References (24)

1. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L: Definition, epidemiology and natural history of COPD. Eur Respir J 2007, 30: 993-1013. 10.1183/09031936.00082507
2. Mamary AJ, Criner GJ: Tiotropium bromide for chronic obstructive pulmonary disease. Expert Rev Respir Med 2009, 3: 211-20. 10.1586/ers.09.19
3. Profita M, Giorgi RD, Sala A, Bonanno A, Riccobono L, Mirabella F, Gjomarkaj M, Bonsignore G, Bousquet J, Vignola AM: Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005, 60: 1361-9. 10.1111/j.1398-9995.2005.00892.x
4. Khan SN, Khan AU: Role of histone acetylation in cell physiology and diseases: An update. Clin Chim Acta 2010, 411: 1401-11. 10.1016/j.cca.2010.06.020
5. Barnes PJ: Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009, 3: 235-43. 10.1177/1753465809348648
6. Mroz RM, Holownia A, Chyczewska E, Braszko JJ: Chronic obstructive pulmonary disease: an update on nuclear signaling related to inflammation and anti-inflammatory treatment. J Physiol Pharmacol 2008,59(Suppl 6):35-42.
7. Landais E, El-Khoury V, Prevost A, Dufer J, Liautaud-Roger F: Nicotine induces chromatin changes and c-Jun up-regulation in HL-60 leukemia cells. Oncol Rep 2005, 14: 1553-8.
8. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2008. [ http://www.goldcopd.org ]
9. Loh LC, Kanabar V, D'Amato M, Barnes NC, O'Connor BJ: Sputum induction in corticosteroid-dependant asthmatics: risks and airway cellular profile. Asian Pac J Allergy Immunol 2005, 23: 189-96.
10. Mroz RM, Holownia A, Chyczewska E, Drost EM, Braszko JJ, Noparlik J, Donaldson K, Macnee W: Cytoplasm-nuclear trafficking of CREB and CREB phosphorylation at Ser133 during therapy of chronic obstructive pulmonary disease. J Physiol Pharmacol 2007,58(Suppl 5):437-44.
11. Holownia A, Mroz RM, Noparlik J, Chyczewska E, Braszko JJ: Expression of CREB-binding protein and peroxisome proliferator-activated receptor gamma during formoterol or formoterol and corticosteroid therapy of chronic obstructive pulmonary disease. J Physiol Pharmacol 2008,59(Suppl 6):303-9.
12. Dowling MR, Charlton SJ: Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol 2006, 148: 927-37.
13. Hansel TT, Barnes PJ: Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today 2002, 38: 585-600. 10.1358/dot.2002.38.9.696535
14. Kato M, Komamura K, Kitakaze M: Tiotropium, a novel muscarinic M3 receptor antagonist, improved symptoms of chronic obstructive pulmonary disease complicated by chronic heart failure. Circ J 2006, 70: 1658-60. 10.1253/circj.70.1658
15. Perng DW, Tao CW, Su KC, Tsai CC, Liu LY, Lee YC: Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 2009, 33: 778-84. 10.1183/09031936.00115308
16. Wollin L, Pieper MP: Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pulm Pharmacol Ther 2010, 23: 345-54. 10.1016/j.pupt.2010.03.008
17. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005, 352: 1967-76. 10.1056/NEJMoa041892
18. Grabiec AM, Tak PP, Reedquist KA: Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: Should we keep our HATs on? Arthritis Res Ther 2008, 10: 226. 10.1186/ar2489
19. Barnes PJ: Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009, 3: 235-43. 10.1177/1753465809348648
20. Quivy V, Van Lint C: Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem Pharmacol 2004, 68: 1221-9. 10.1016/j.bcp.2004.05.039
21. Copeland RA, Olhava EJ, Scott MP: Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol 2010, 14: 505-10. 10.1016/j.cbpa.2010.06.174
22. Dinarello CA: Anti-inflammatory Agents: Present and Future. Cell 2010,140(6):935-50. 10.1016/j.cell.2010.02.043
23. Gosens R, Zaagsma J, Meurs H, Halayko AJ: Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 2006, 7: 73-88. 10.1186/1465-9921-7-73
24. Wessler IK, Kirkpatrick CJ: The non-neuronal cholinergic system: an emerging drug target in the airways. Pulm Pharmacol Ther 2001, 14: 423-34. 10.1006/pupt.2001.0313